Approaches to Treatment-2021-Winter-QTR-Term-wks-1-thru-11-
(11/29/2021-02/13/2022)-PT27
Test Midterm Exam - Week 6
Started 1/8/22 11:00 AM
Submitted 1/8/22 12:38 PM
Due Date 1/10/22 1:59 AM
Status Completed
Attempt 60 out of 100 points
Score
Time 1 hour, 38 minutes out of 2 hours and 30 minutes
Elapsed
Results Feedback
Displayed
Question 1
Is this a TRUE or FALSE statement? The following patient case is considered an
example of treatment-resistant depression.
B. B. is a 26-year old-female at your clinic today with the diagnosis, “treatment-resistant
depression.” She is currently on Bupropion 300 mg daily and has been at this dose for 6
weeks with no alleviation in depressive symptoms.
She has trialed the following medications in the past with treatment duration listed:
- Paroxetine 40 mg daily for 6 weeks
- Citalopram 20 mg daily for 2 weeks
Response “At least one trial with an antidepressant with established efficacy
Feedback: in MDD (with sufficient duration and doses) is considered to be
adequate antidepressant treatment.”
• Question 2
Ronnie presents to your clinic with tremor, bradykinesia, and rigidity. The
symptoms are very similar to what you would see in a patient with
Parkinson’s disease. The client was prescribed risperidone several weeks
ago. What is the reason for Ronnie’s symptoms?
Response
Feedback:
Risperidone is an antipsychotic that works by blocking dopamine
receptors in the striatum. Dopamine blockade has been associated
with the extrapyramidal symptoms that are seen with antipsychotic
usage.
, • Question 3
Scott is a 70-year-old man that is taking citalopram 40 mg daily. You discuss changing
citalopram to another medication or decreasing the dose. He is hesitant to change
medications since citalopram works for him. You end up decreasing his dose to 20
mg/day. He asks why you are wanting to change his medication or lower his dose. Which
of the following reasons is the main reason you made the decision to decrease his dose.
Response
Feedback:
A maximum daily dose of 20 mg/day is recommended in
patients greater than 60 years of age due to the
increased risk of QT prolongation.
• Question 4
M. B. was just diagnosed with Generalized Anxiety Disorder and pharmacotherapy is
needed. Which of the following would be a first-line treatment option for M. B.?
I. Duloxetine
II. Quetiapine
III. Diazepam
IV. Escitalopram
Response
“As is true for panic and the other anxiety disorders, the SSRIs and
Feedback: SNRIS are generally considered first-line agents for the treatment of
GAD because of their favorable side effect profile….”
• Question 5
Which one of the anticonvulsants mentioned below has sufficient data to support its use
in bipolar disorder?
Response Carbamazepine has data to support its use in the
Feedback: treatment of bipolar disorder. The other medications
listed do not have data to support the use in any phase
of bipolar disorder.
• Question 6
A 23-year-old female was just diagnosed with major depressive disorder and is being
started on escitalopram 10 mg daily. The patient should be counseled about which Black
Box warning?
Response “In 2004, the FDA asked manufacturers of almost all the new
Feedback: antidepressant drugs to include in their labeling a warning statement
that recommends close observation of adult and pediatric patients
treated with these drugs for worsening depression or the emergence of
suicidality."
• Question 7